Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT AFFIRM: Apixaban Monotherapy vs Combination in AF and CAD
NCT06866665Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Mar 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of apixaban and clopidogrel in Atrial fibrillation (AFib) and coronary artery disease (CAD) (2 arms), sponsored by Yonsei University. Primary endpoint: Net Adverse Clinical Event at 12 months. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
apixabanclopidogrel
03
Conditions
Atrial fibrillation (AFib)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06866665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866665.